- Home
- NBXG vs VIR Comparison
NBXG vs VIR Comparison
Compare NBXG & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | VIR |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 825.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NBXG | VIR |
|---|---|---|
| Price | $14.63 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.73 |
| AVG Volume (30 Days) | 243.7K | ★ 1.8M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.31 | $4.16 |
| 52 Week High | $12.23 | $14.45 |
Technical Indicators
Market Signals| Indicator | NBXG | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 48.75 |
| Support Level | $14.37 | $5.55 |
| Resistance Level | $14.91 | $6.30 |
| Average True Range (ATR) | 0.20 | 0.30 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 68.70 | 57.05 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.